Impact of autologous hematopoietic stem cell transplantation in standard and high-risk multiple myeloma patients by FISH treated with bortezomib/thalidomide

Objective To evaluate the impact of autologous hematopoietic stem cell transplantation (ASCT) on survival in standard and high-risk multiple myeloma (MM) patients by FISH.Methods Seventyfour patients were enrolled in this retrospective research and all patients were inducted by bortezomib /thalidomide.Patients were divided into four groups according to FISH-based risk stratification and consolidation strategy.Impact on survival was evaluated through survival analysis.Results The total response rate of all patients was 91.9 ％ (68/74),nCR+CR rate was 62.2 ％ (46/74).No significant difference was found in response rate or nCR+CR rate between standard group and high-risk group (P =0.592,0.251).In high-risk group,PFS and OS were found to be prolonged 19.7 months and 12.5 months respectively in ASCT-group than those in chemo-group (P =0.028,0.542),while no significant difference was found between ASCT-group and chemo-group in standard-risk group.Conclusion After induction therapy with bortezomib / thalidomide,single ASCT has no impact on survival in standard-risk MM patients but prolongs PFS in high-risk group. Key words: Multiple myeloma;  Hematopoietic stem cell transplantation, autologous;  Cytogenetics